CEL-SCI Home Page
preload preload

CEL-SCI CEO on Fox

Press Releases

Feb. 2018 CEO Presentation

Press Releases

June 8, 2018
NEW STORY U.S. Patent Office Allows New CEL-SCI Patents for LEAPS Vaccine Platform Technology

May 30, 2018
NEW STORY CEL-SCI Announces Reminder of Warrant Exercise Price

May 22, 2018
NEW STORY CEL-SCI Corporation to Present at the 8th annual LD Micro Invitational

May 15, 2018
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal 2018 Financial Results

May 2, 2018
NEW STORY CEL-SCI Corporation Announces Upcoming Investor Conference Presentations

April 9, 2018
NEW STORY CEL-SCI Corporation to Present at The Microcap Conference

April 4, 2018
NEW STORY CEL-SCI Issues Letter to Shareholders

April 3, 2018
NEW STORY CEL-SCI Announces Adjustment to Warrant Exercise Price

February 23, 2018
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016

February 12, 2018
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results

February 5, 2018
NEW STORY CEL-SCI to Present at 2018 BIO CEO & Investor Conference

January 30, 2018
NEW STORY U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology

January 8, 2018
NEW STORY CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis

January 3, 2018
NEW STORY CEL-SCI Issues Letter to Shareholders

December 29, 2017
NEW STORY CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments

December 18, 2017
NEW STORY CEL-SCI Announces Robert Watson Joins Its Board of Directors

December 11, 2017
NEW STORY CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study

December 7, 2017
NEW STORY CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

November 13, 2017
NEW STORY CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization

October 10, 2017
NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' To the Immune System

October 5, 2017
NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Former Clinical Research Organization

September 19, 2017
NEW STORY CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine

August 23, 2017
NEW STORY CEL-SCI Announces $3.5 Million Registered Direct Offering

August 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial

August 9, 2017
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

June 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split

June 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

June 5, 2017
CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial

May 24, 2017
CEL-SCI Corporation Releases Letter to Shareholders

May 16, 2017
CEL-SCI Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting

May 10, 2017
CEL-SCI Corporation Reports Second Quarter Fiscal Year 2017 Financial Results

May 1, 2017
CEL-SCI Announces $1.51 Million Registered Direct Offering

April 28, 2017
CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office

April 24, 2017
CEL-SCI Corporation Releases Letter to Shareholders

April 12, 2017
CEL-SCI Scientist Presents at the World Vaccine Congress

March 9, 2017
CEL-SCI Announces $1.5 Million Registered Direct Offering

February 27, 2017
CEL-SCI Announces That the NYSE MKT Approves Plan

February 21, 2017
CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference

February 17, 2017
CEL-SCI Announces $1.0 Million Registered Direct Offering

February 9, 2017
CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results

 

ADDITIONAL RELEASES
View All Corporate Press Releases


 

THE CEL-SCI STORY